Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
SKAN Group AG is a Swiss-based company and global market leader in developing and manufacturing isolators, cleanroom devices, and decontamination processes for aseptic production in the pharmaceutical and chemical industries. Operating through two main segments—Equipment and Solutions, and Services and Consumables—it provides advanced products including isolators, laminar flow systems, safety workbenches, transfer systems, fume cupboards, biological indicators, and personal protective equipment, alongside digital solutions, lifecycle support, and laboratory services. Founded in 1968 and headquartered in Allschwil, Switzerland, with over 1,600 employees across subsidiaries in Europe, the Americas, Asia, and beyond, SKAN Group AG serves high-regulatory markets like Europe, North America, Japan, and emerging regions such as China and India. Renowned for its expertise in ventilation, sterilization, validated software, microbiology, and regulatory compliance, the company supports blue-chip biopharmaceutical firms and research labs, contributing significantly to processes like vaccine filling—every third vaccine in core markets uses SKAN isolators—and maintains high market entry barriers through innovation and comprehensive lifecycle partnerships. Its commitment to precision engineering and quality positions it as a key player in the healthcare equipment sector, particularly advanced medical technology for sterile manufacturing.
Operating margin is thin at 7.63%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 7.7% YoY. Margins deteriorated 4.7pp alongside, both lines moving the wrong way.
ROIC dropped from 19.58% to 8.85%, capital efficiency is deteriorating. Operating margin contracted 4.7pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
CHF 333M
▼ -7.7% YoY
Net Income (TTM)
CHF 18M
▼ -56.9% YoY
Op. Margin
7.63%
▼ -4.7pp YoY
ROIC
8.85%
▼ -10.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
CHF 18M
▲ +357.3% YoY
Op. Cash Flow (TTM)
CHF 59M
▲ +87.1% YoY
Net Debt
CHF 37M
Cash & Equiv.
CHF 94M
3Y CAGR: +6.4%
3Y CAGR: -17.6%
Continue Research